Enterprise Value
2.431B
Cash
363.3M
Avg Qtr Burn
N/A
Short % of Float
17.23%
Insider Ownership
11.61%
Institutional Own.
86.57%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Relacorilant + Nab-paclitaxel Details Ovarian cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Korlym® (Relacorilant) Details Hypercortisolism | Phase 3 Data readout | |
Miricorilant Details Non-alcoholic steatohepatitis | Phase 2b Initiation | |
Dazucorilant Details Amyotrophic lateral sclerosis | Phase 2 Data readout | |
Miricorilant Details Obesity, Antipsychotic-Induced Weight Gain | Phase 2 Update | |
Relacorilant (GR antagonist) + Enzalutamide Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
Relacorilant + pembrolizumab Details Cancer, Adrenal cancer | Phase 1b Data readout | |
Relacorilant + Nab-paclitaxel Details Pancreatic cancer | Failed Discontinued |